Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination with paclitaxel, and a confirmed ORR of 35.7% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback